Summary & Overview
CPT 81303: Targeted MECP2 Familial Mutation Testing
CPT code 81303 denotes a targeted molecular test performed by a laboratory to detect familial mutations in the MECP2 gene, which is clinically important for identifying inherited variants associated with neurodevelopmental disorders. This code captures the technical component of testing that seeks specific, previously identified mutations in family members rather than broad sequencing panels. Nationally, accurate coding for targeted genetic assays supports appropriate claims processing, clinical follow-up, and tracking of genetic diagnostic utilization.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for MECP2 familial mutation testing, typical sites of service, and the types of information payers commonly consider when evaluating coverage for targeted genetic tests. The publication outlines benchmarks and policy-relevant considerations such as coding specificity, the distinction between targeted tests and broader sequencing services, and common billing modifiers used in laboratory claims (modifier details provided separately).
The content is intended for billing professionals, laboratory managers, and policy analysts seeking a national view of how CPT code 81303 is used, documented, and adjudicated across major payers, along with practical context for clinical application and claim submission. Data not available in the input will be noted where relevant.
Billing Code Overview
CPT code 81303 describes a laboratory technical test performed to detect the presence of known familial mutations in the MECP2 (methyl CpG binding protein 2) gene. The service targets testing for mutations already identified in a patient's family members and focuses on confirming whether the same pathogenic variants are present in the patient.
Service type: Targeted genetic testing / molecular diagnostic assay
Typical site of service: Clinical laboratory or molecular diagnostics laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric or adult patient with a known familial pathogenic variant in the methyl CpG binding protein 2 gene (MECP2) is referred for targeted molecular testing to determine whether the patient carries the same mutation. Typical referral sources include a pediatric neurologist, medical geneticist, genetic counselor, or obstetric provider for prenatal or preconception evaluation. The clinical workflow begins with the ordering provider documenting the specific familial MECP2 variant in the medical record and placing an order for targeted familial variant analysis (CPT 81303). A specimen (usually peripheral blood in an EDTA tube, but occasionally saliva or amniotic fluid for prenatal testing) is collected at an outpatient clinic, hospital phlebotomy, or genetic testing laboratory specimen collection site. The specimen is shipped to a molecular diagnostics laboratory where the laboratory analyst performs targeted testing using sequence-specific assays (such as Sanger sequencing or targeted PCR) to detect the specified familial mutation. Results are reported to the ordering provider and genetic counselor, who review implications for diagnosis, prognosis, and family planning with the patient or caregivers. Typical sites of service are outpatient clinical laboratories, hospital outpatient labs, specialty genetic testing laboratories, and occasionally inpatient settings if clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component |